| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Protein kinase C (Ki = 2.75 nM)[1]
The direct molecular target of Bryostatin 3 is protein kinase C (PKC). It binds to the C1 domain of PKC, competing with phorbol esters (e.g., PDBu). The reported binding affinity (Ki) for PKC is 2.75 nM. |
|---|---|
| ln Vitro |
Significantly inhibiting the growth-inhibitory activity of TPA, bryostatin 3 (1 μM; 24 h) did not impede 3Hlthymidine incorporation[2]. TPA's ability to limit cell proliferation is blocked by bryostatin 3 (1 μM; 24 h), but TPA-enhanced cell-substratum adhesion is unaffected[2].
At the cellular level, Bryostatin 3 exhibits complex modulatory activity. In GH4C1 pituitary cells, it attenuates the inhibition of cell proliferation caused by the phorbol ester TPA . In relevant assays, treatment with 1 μM Bryostatin 3 for 24 hours largely blocked the growth-inhibitory action of TPA but did not inhibit [³H]thymidine incorporation or block TPA-enhanced cell-substratum adhesion . Notably, unlike phorbol esters which have tumor-promoting activity, Bryostatin 3 displayed a phorbol ester-like activity profile in functional simulation studies . |
| ln Vivo |
Existing research has primarily focused on its structural analog, Bryostatin 1, which has demonstrated immunomodulatory and antitumor activities. Therefore, although Bryostatin 3 is an important in vitro tool for studying PKC signaling, detailed pharmacodynamic data in animal models are lacking.
|
| Enzyme Assay |
The standard method to evaluate the binding affinity of Bryostatin 3 for PKC is a competitive binding assay. PKC enzyme purified from rat brain is incubated with a fixed concentration of a radiolabeled phorbol ester (e.g., [³H]-PDBu) and varying concentrations of Bryostatin 3 (e.g., 0.1 nM to 10 μM) in a buffer containing phosphatidylserine and Ca²⁺ at room temperature. After incubation, bound and free ligands are separated by filtration or PEG precipitation, and radioactivity is measured with a scintillation counter. The IC₅₀ (or Ki) is calculated by plotting the concentration of Bryostatin 3 against the inhibition rate of [³H]-PDBu binding.
|
| Cell Assay |
GH4C1 rat pituitary cells or related cell lines are commonly used to assess functional activity. Cells are plated overnight and then treated with varying concentrations of Bryostatin 3 (e.g., 1 nM to 1 μM) in the presence or absence of a fixed concentration of TPA (e.g., 100 nM) for 24-48 hours. Cell proliferation is assessed by [³H]-thymidine incorporation assay or cell counting. In parallel, changes in cell-substratum adhesion can be evaluated by cell adhesion assays. By comparing the differences among the Bryostatin 3-alone, TPA-alone, and combination groups, one can determine whether it acts as an agonist, antagonist, or exhibits functional selectivity.
|
| Animal Protocol |
If in vivo studies were to be conducted, administration protocols could be adapted from its analog Bryostatin 1, for example, via tail vein or intraperitoneal injection in tumor models, with efficacy assessed by measuring tumor volume, changes in biomarkers, or immune cell activity.
|
| ADME/Pharmacokinetics |
As a macrocyclic lactone natural product, its physicochemical properties (Molecular Weight 888.99, high lipophilicity) suggest that it may have a large volume of distribution and low oral bioavailability, but this inference needs to be validated through dedicated experiments.
|
| Toxicity/Toxicokinetics |
One Material Safety Data Sheet (MSDS) classifies it as "Not a hazardous substance or mixture" , but this refers to direct physicochemical hazards during laboratory handling as a reagent, not its pharmacological or physiological toxicity in vivo. Notably, functional simulation studies suggest that Bryostatin 3 displays a phorbol ester-like activity profile , implying that its in vivo application may require careful evaluation of potential toxicities associated with PKC over-activation.
|
| References |
| Molecular Formula |
C46H64O17
|
|---|---|
| Molecular Weight |
888.990160000001
|
| Exact Mass |
888.414
|
| CAS # |
143370-84-7
|
| PubChem CID |
90489026
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
993.2±65.0 °C at 760 mmHg
|
| Flash Point |
286.2±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.579
|
| LogP |
4.17
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
63
|
| Complexity |
1860
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CCC/C=C/C=C/C(O[C@H]1C2=CC(O[C@@H]2[C@@H]2O[C@]1(C(C=C[C@H]1C/C(=C\C(OC)=O)/C[C@@H](C[C@@]3(O[C@H](C[C@H](CC(O[C@H](C2)[C@H](O)C)=O)O)C[C@H](OC(=O)C)C3(C)C)O)O1)(C)C)O)=O)=O |t:21,&1:9,14,15,17,21,30,32,34,36,40,42,48|
|
| InChi Key |
BSNHYLUEHJOXFN-UUIHWDITSA-N
|
| InChi Code |
InChI=1S/C46H64O17/c1-9-10-11-12-13-14-37(50)61-42-33-23-40(53)60-41(33)35-24-34(26(2)47)59-39(52)21-29(49)20-31-22-36(57-27(3)48)44(6,7)45(54,62-31)25-32-18-28(19-38(51)56-8)17-30(58-32)15-16-43(4,5)46(42,55)63-35/h11-16,19,23,26,29-32,34-36,41-42,47,49,54-55H,9-10,17-18,20-22,24-25H2,1-8H3/b12-11+,14-13+,16-15-,28-19+/t26-,29-,30+,31-,32+,34-,35-,36+,41+,42+,45+,46-/m1/s1
|
| Chemical Name |
[(1S,3Z,5R,7Z,9S,11S,13S,15R,17R,21R,23R,24S,29S)-13-acetyloxy-1,11,17-trihydroxy-21-[(1R)-1-hydroxyethyl]-7-(2-methoxy-2-oxoethylidene)-2,2,12,12-tetramethyl-19,26-dioxo-20,25,30,31,32-pentaoxapentacyclo[21.6.1.15,9.111,15.024,28]dotriaconta-3,27-dien-29-yl] (2E,4E)-octa-2,4-dienoate
|
| Synonyms |
143370-84-7; orb1704651; SCHEMBL29366157; TFA37084; (4S,5S,7E,9R,11Z,13S,15S,17S,19R,21R,25R,27R,27aS)-17-(Acetyloxy)-4,5,6,9,10,11,12,13,14,15,16,17,18,19, 20,21,22,23,25,26,27,27a-docosahydro-5,15,21-trihydroxy-25-[(1R)-1-hydroxyethyl]-11-(2-methoxy-2-oxoethylidene)-6,6,16,16-tetramethyl-2,23-dioxo-
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1249 mL | 5.6244 mL | 11.2487 mL | |
| 5 mM | 0.2250 mL | 1.1249 mL | 2.2497 mL | |
| 10 mM | 0.1125 mL | 0.5624 mL | 1.1249 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
